Bendroflumethiazide

CHEMBL1684 Phase 4 Disetujui Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
421.4 g/mol
LogP
1.2
Phase
4

A thiazide diuretic that reduces blood pressure by increasing urinary sodium and water excretion, decreasing blood volume and vascular resistance. It is used for hypertension and edema associated with heart failure.

Berat Molekul

421,4000 g/mol

LogP

1,20

TPSA

135,00 Ų

Lipinski RO5

Lulus

Area Terapeutik

Mekanisme Kerja

Inhibits sodium reabsorption in the renal tubules, promoting excretion of sodium, chloride, and water. This reduces extracellular fluid volume and cardiac preload, lowering blood pressure.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanisme

Inhibits sodium reabsorption in the renal tubules, promoting excretion of sodium, chloride, and water. This reduces extracellular fluid volume and cardiac preload, lowering blood pressure.

Struktur 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

NS(=O)(=O)c1cc2c(cc1C(F)(F)F)NC(Cc1ccccc1)NS2(=O)=O

InChI

InChI=1S/C15H14F3N3O4S2/c16-15(17,18)10-7-11-13(8-12(10)26(19,22)23)27(24,25)21-14(20-11)6-9-4-2-1-3-5-9/h1-5,7-8,14,20-21H,6H2,(H2,19,22,23)

Molecular Formula

C15H14F3N3O4S2

HBD / HBA

3 / 10

Ikatan yang Dapat Dirotasi

3

Atom Berat

27

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

A thiazide diuretic that reduces blood pressure by increasing urinary sodium and water excretion, decreasing blood volume and vascular resistance. It is used for hypertension and edema associated with heart failure.

Inhibits sodium reabsorption in the renal tubules, promoting excretion of sodium, chloride, and water. This reduces extracellular fluid volume and cardiac preload, lowering blood pressure.

Yes, Bendroflumethiazide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1684. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 2315. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.